CRISPR Therapeutics AG (CRSP)

NASDAQ: CRSP · IEX Real-Time Price · USD
77.21
-2.93 (-3.66%)
Aug 16, 2022 11:43 AM EDT - Market open
-3.66%
Market Cap 6.02B
Revenue (ttm) 14.82M
Net Income (ttm) -633.45M
Shares Out 78.01M
EPS (ttm) 3.76
PE Ratio 20.53
Forward PE 23.36
Dividend n/a
Ex-Dividend Date n/a
Volume 473,674
Open 80.11
Previous Close 80.14
Day's Range 75.37 - 80.47
52-Week Range 42.51 - 129.50
Beta 1.92
Analysts Buy
Price Target 116.77 (+51.2%)
Earnings Date Aug 4, 2022

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidat... [Read more...]

Industry Biotechnology
IPO Date Oct 19, 2016
CEO Samarth Kulkarni
Employees 473
Stock Exchange NASDAQ
Ticker Symbol CRSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 32 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 116.77, which is an increase of 51.24% from the latest price.

Price Target
$116.77
(51.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -7.62% and 96.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines an...

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the...

Other symbols: ALNYBEAMNTLA

Where Will CRISPR Therapeutics Be in 1 Year?

The next 12 months could look very different from the past year for this biotech company.

7 Undervalued Biotech Stocks to Buy Before They Boom

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. The post 7 Undervalued Biotech Stocks to Buy Before They Boom appeared ...

2 Biotech Stocks to Help Recession-Proof Your Portfolio

These companies' shares have outpaced the market and other biotech stocks this year.

Other symbols: EXEL

6 Cathie Wood Stocks to Buy on the Dip

As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. The post 6 Cathie Wood Stocks to Buy on the Dip appeared first ...

Other symbols: EXASFCFROKUTSLAZM

The Best 3 Stocks in Cathie Wood's Ark ETF Have 1 Thing in Common

They are also outperforming the S&P 500.

Other symbols: CERSSGFY

7 Moonshot Investments Upending a $10 Trillion Industry

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on I...

Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week

These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.

Other symbols: BLUEEDIT

7 Best Biotech Stocks to Buy in July 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared f...

Other symbols: AMGNEXELIBBIONSMRKTWST

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation

These players may change the world of medicine.

Other symbols: ISRGVXRT

Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.

Should You Sell Biotech Stocks If There's a Recession?

It's probably better to think about whether to buy more shares.

Other symbols: SGENXBI

Why CRISPR Therapeutics Stock Is Falling

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day. CRISPR Therapeutics stock plun...

Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels?

CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene-editing company focused on developing gene-based medicines for human diseases, has risen a solid 24% in a month, outperforming the broader ...

CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?

CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner

CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets. The CRISPR Ther...

3 Bargain Stocks You Can Buy Today and Hold Forever

These companies have become great deals because of the market downturn.

Other symbols: GRMNMSFT

Final Trades: Boeing, Charles Schwab, Crispr Therapeutics & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: BAICLNSCHW

2 Top Biotech Stocks Ready for Bull Runs

The market hasn't been kind to these two stocks lately.

Other symbols: AXSM

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic ...

Roku, Tesla, and Other Cathie Wood Favorites Are Falling

The ARK Innovation ETF has fallen about 65% in the past year as investors fled from growth stocks.

Other symbols: ARKKROKUSQTSLA